VCYT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Veracyte Inc (VCYT) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company's financial performance is solid and analysts have a positive outlook with a price target increase, the technical indicators and options data suggest a neutral to slightly bearish sentiment in the short term. The lack of recent positive news or significant trading trends further supports a hold recommendation.
The MACD is negatively contracting and below zero, indicating weak momentum. RSI is neutral at 41.629, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level of 36.52, with key support at 34.682 and resistance at 38.357. Overall, technical indicators suggest a neutral to slightly bearish sentiment.
Financial performance in Q3 2025 shows strong growth: Revenue increased by 13.82% YoY, Net Income by 26.28% YoY, and EPS by 26.32% YoY.
Analyst Subbu Nambi raised the price target to $50 from $45, maintaining a Buy rating.
Technical indicators show weak momentum and no clear upward trend.
Stock trend analysis suggests a 40% chance of a slight gain in the next day but potential losses in the next week and month.
No recent news, congress trading data, or significant insider/hedge fund activity to act as a catalyst.
In Q3 2025, Veracyte reported strong financial growth: Revenue increased to $131.87M (up 13.82% YoY), Net Income rose to $19.14M (up 26.28% YoY), EPS increased to $0.24 (up 26.32% YoY), and Gross Margin improved to 68.75% (up 1.96% YoY).
Guggenheim analyst Subbu Nambi raised the price target to $50 from $45 and maintained a Buy rating, reflecting confidence in the company's growth potential.
